Alcami expands lab services footprint in Durham

Alcami Corp., a leading U.S.-based contract development and manufacturing organization (CDMO), will expand its laboratory services at its Creekstone Drive facility in Durham, N.C. 

The 20,000-square-foot expansion began in Q4 2025 and is expected to be finalized in 2026. It will strengthen Alcami’s analytical capabilities in support of biologics, peptides, oligonucleotides, antibody-drug conjugates (ADCs), and cell and gene therapy (CGT) drug substances and drug products. 

The Creekstone Drive site will feature expanded capacity for method establishment, release and stability testing, as well as biologics characterization using instrumentation in bioseparation, mass spectrometry, electrophoresis, and bioassay methodologies. These enhancements will allow Alcami to better serve clients across all phases of drug development, from preclinical through commercial supply, the company said.

“Our investment in the Durham laboratory services facility reflects Alcami’s dedication to scientific excellence, innovation, and operational agility,” said Katie Schlipp, President of Laboratory Services. “By expanding our capabilities, we’re enabling our clients to bring life-changing therapies to patients with greater speed and scalability.”

This expansion complements recent investments across Alcami’s network, including sterile fill-finish capacity expansions at the sites in RTP and Charleston, S.C., and enhanced oral solid dose capabilities in Wilmington, N.C.